Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, with a primary focus on pulmonary arterial hypertension (PAH). The IKT news feed highlights the company’s progress as it advances its lead investigational therapy, IKT-001, a prodrug of imatinib mesylate, through late-stage clinical development in PAH.
Visitors to this page can review company-issued press releases and related disclosures that describe Inhibikase’s clinical plans, regulatory interactions, and corporate developments. Recent news has covered the evolution of the IMPROVE-PAH clinical program for IKT-001, including the transition from a planned Phase 2b trial to a global pivotal Phase 3 study design following a Type C interaction with the U.S. Food & Drug Administration. The company also reports on its financial results, capital raises through private placements and underwritten public offerings, and changes in senior leadership and board composition.
Because Inhibikase is a clinical-stage company with no marketed products, its news flow is closely tied to research and development milestones, such as study protocol finalization, anticipated trial initiation timelines, and updates on the design of adaptive clinical studies in PAH. Corporate updates, including executive appointments and governance matters, are also reflected in its announcements. Investors and observers can use this news page to follow how Inhibikase describes the advancement of IKT-001 in pulmonary arterial hypertension and how the company positions itself within the cardiopulmonary disease space.
Inhibikase Therapeutics (Nasdaq: IKT) has partnered with Clintrex Research Corporation to enhance its clinical development for Parkinson's disease and related disorders. Clintrex will manage clinical trials and regulatory aspects for Inhibikase's drug candidates, including IkT-148009 and IkT-001Pro. Dr. C. Warren Olanow, CEO of Clintrex, will take on the role of Interim Chief Medical Officer for Inhibikase. This collaboration aims to expedite the clinical advancement of treatments targeting serious neurological conditions.
Inhibikase Therapeutics, a clinical-stage pharmaceutical company, has successfully closed its initial public offering, selling 1,800,000 shares at $10.00 each, generating $18 million in gross proceeds. Additionally, underwriters have a 45-day option to purchase up to 270,000 additional shares. The company's stock began trading on the Nasdaq Capital Market under the ticker symbol 'IKT' on December 23, 2020. ThinkEquity is the sole book-running manager for this offering.
Inhibikase Therapeutics has priced its initial public offering (IPO) at $10.00 per share, offering 1,800,000 shares and raising $18 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under the ticker symbol IKT starting December 23, 2020, with the offering expected to close on December 28, 2020. The underwriters also have a 45-day option for an additional 270,000 shares. ThinkEquity serves as the sole book-running manager for the offering.